CaV1.3 L-type Ca2+ channels modulate depression-like behaviour in mice independent of deaf phenotype-Reference-Cited by-同舟云学术

CaV1.3 L-type Ca2+ channels modulate depression-like behaviour in mice independent of deaf phenotype

Published:2009-08-11 Issue:04 Volume:13 Page:499
ISSN:1461-1457
Container-title:The International Journal of Neuropsychopharmacology
language:en
Short-container-title:Int. J. Neuropsychopharm.

Author:

Busquet Perrine,Khoi Nguyen Ngoc,Schmid Eduard,Tanimoto Naoyuki,Seeliger Mathias W.,Ben-Yosef Tamar,Mizuno Fengxia,Akopian Abram,Striessnig Jörg,Singewald Nicolas

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology

Link

http://academic.oup.com/ijnp/article-pdf/13/4/499/2105275/13-4-499.pdf

Reference71 articles.

1. International Union of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels

2. Calcium Extrusion from Mammalian Photoreceptor Terminals

3. Photoreceptor calcium channels: Insight from night blindness

4. CaV1.2 and CaV1.3 neuronal L-type calcium channels: differential targeting and signaling to pCREB

5. Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. L-type calcium channel regulation of depression, anxiety and anhedonia-related behavioral phenotypes following chronic stress exposure;Neuropharmacology;2024-10

2. Advancing Post-Stroke Depression Research: Insights from Murine Models and Behavioral Analyses;Life;2024-09-03

3. The human channel gating–modifying A749G CACNA1D (Cav1.3) variant induces a neurodevelopmental syndrome–like phenotype in mice;JCI Insight;2023-10-23

4. Putative pathological mechanisms of late-life depression and Alzheimer’s disease;Brain Research;2023-08

5. L-type calcium channel regulation of dopamine activity in the ventral tegmental area to nucleus accumbens pathway: Implications for substance use, mood disorders and co-morbidities;Neuropharmacology;2023-02